Bladder-sparing treatment for muscle-invasive bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a medication called nimotuzumab (a type of targeted therapy) added to standard chemoradiation (chemotherapy plus radiation) to treat muscle-invasive bladder cancer without surgically removing the bladder. The goal is to control the cancer while preserving the bladder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have a type of bladder cancer called urothelial carcinoma.
- Your cancer is either stage T2–T4a (growing into the bladder muscle but not spreading to other organs) or a high-grade tumor that has returned after initial treatment.
- You are not able or not willing to have your bladder removed, or you cannot tolerate standard chemotherapy, or you have had a tumor recurrence and further surgery isn't an option.
- You are generally in good health (able to do daily activities) with adequate blood, kidney, liver, and clotting function.
- You have not had chemotherapy, targeted therapy, or immunotherapy for cancer before, and you have no active infections like HIV, hepatitis B, or hepatitis C.
- You agree to use contraception during the trial if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study watches people with muscle-invasive bladder cancer who choose to keep their bladder after receiving neoadjuvant therapy (treatment before the main treatment). It aims to see how well bladder-preserving treatments like chemoradiation work over time.
This study tests a combination of a targeted drug (disitamab vedotin), an immunotherapy drug (PD-1 inhibitor), and radiation therapy as a way to treat bladder cancer without removing the bladder. It is for people whose cancer has grown into the bladder muscle but hasn't spread to other parts of the body, and whose tumor shows high HER2 levels.
This study tests a combination of bladder-sparing treatments for muscle-invasive bladder cancer, including surgery, chemotherapy, immunotherapy, and radiation, followed by maintenance immunotherapy. The goal is to see if this approach can control cancer while preserving the bladder, compared to a watch-and-wait approach.
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
This trial tests a combination of two drugs (trastuzumab rezetecan and adebrelimab) plus radiation to the bladder, aiming to preserve the bladder instead of removing it. It's for people with muscle-invasive bladder cancer that shows a specific marker called HER2.
This trial tests a new treatment approach using MRI to guide bladder preservation for patients with muscle-invasive bladder cancer. The goal is to treat the cancer with chemotherapy and radiation instead of removing the bladder, potentially allowing you to keep your bladder while fighting the cancer.
Hear when a new Bladder (Urothelial, Transitional Cell) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.